- Drug discovery for the developing world: progress at the Novartis Institute for Tropical Diseases. Jones, Catherine L.; Yeung, Bryan K. S.; Manjunatha, Ujjini; Shi, Pei-Yong; Bodenreider, Christophe; Diagana, Thierry T. // Nature Reviews Drug Discovery;Jun2015, Vol. 14 Issue 6, p442
A letter to the editor is presented in response to the article "Advances in the development of new tuberculosis drugs and treatment regimens," by A. Zumla and colleagues in the 2013 issue.
- ERRATA. // Clinical Infectious Diseases;3/1/2016, Vol. 62 Issue 5, p673
A correction to the article "An Evidence-Based Drug Development Tool for Tuberculosis Regimens: The Hollow Fiber System Model" that was published in the 2015 issue.
- Potential Treatment for Drug-resistant TB Discovered. // News India Times;3/6/2015, Vol. 46 Issue 10, p14
The article reports on the discovering of a new drug that would be used as a treatment for multi-drug resistant tuberculosis.
- Made in Africa. Nordling, Linda // Nature Medicine;Jul2013, Vol. 19 Issue 7, p803
The article focuses on drug development efforts by the H3-D drug discovery center in Cape Town, South Africa. H3-D director Kelly Chibale and his team are said to be attempting to change the stereotype about African medicine by promoting modern drug development. Information on the experimental...
- Fight against neglected global diseases moves another step forward through a partnership between CDRD and NGDI-UBC. // Biomedical Market Newsletter;3/21/2012, Vol. 21, p1
The article offers information on the partnership initiative taken by the Centre for Drug Research and Development and the Neglected Global Diseases Initiative at the University of British Columbia which aims at fighting against global diseases and betterment of drugs used for curing Tuberculosis.
- Tuberculosis: New vaccine strategy to advance solutions for tuberculosis. // Biomedical Market Newsletter;3/28/2012, Vol. 21, p1
The article informs that researchers have published in the periodical "Tuberculosis" a global plan of action for developing vaccines that are seen as critical to eliminating tuberculosis.
- Product development partnership. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;9/7/2010, Vol. 182 Issue 12, pE577
The article offers news brief regarding the agreement between Global Alliance for TB Drug Development and Drugs for Neglected Diseases Initiative (DNDi) that permits the DNDi to establish a class of anti-tuberculosis (TB) compounds to deal with the tropical diseases such as visceral...
- Nitrofurans as Novel Anti-tuberculosis Agents: Identification, Development and Evaluation. Tangallapally, Rajendra P.; Yendapally, Raghunandan; Daniels, AnTawan J.; Lee, Robin E. B.; Lee, Richard E. // Current Topics in Medicinal Chemistry;Mar2007, Vol. 7 Issue 5, p509
During a search for new anti-tuberculosis agents, a screen of a commercially available library provided a hit nitrofuranyl amide. This hit was selected for further development due to its potential as an anti-tuberculosis agent with a novel mechanism of action, and its potential for activity...
- Molecular Approaches to Target Discovery: - Evaluating Targets for Antituberculosis Drug Discovery Programmes. Balganesh, T. S.; Furr, B. J. A. // Infectious Disorders - Drug Targets;Jun2007, Vol. 7 Issue 2, p120
Selection of appropriate targets for launching antituberculosis drug discovery programmes is challenging. This challenge is magnified by the limited repertoire of ï¿½validated targetsï¿½ and the paucity of clinically successful drugs. However, continued understanding of the biology of the...